IVD company Lansionbio will provide more products that can be used in families and help hospitals put their patients in different groups by connecting hospital terminals with the fresh proceeds.
IVD firm Lansionbio (Chinese: 岚煜生物) announced the completion of the Series D2 financing round worth nearly CNY 100 million. The round was led by Government Fund (Chinese: 政府基金). CEC Capital (Chinese: 易凯资本) served as the exclusive financial advisor for this round.
The round will be used to expand the company's layout in domestic and overseas markets and accelerate its channel network down to the terminal.
Founded in 2016, Lansionbio is a high-tech biotechnology company specializing in research & development, production, sales and services of in vitro diagnostic reagents and devices. With its global leading technology, Lansionbio has obtained an ISO13485 certificate and built an R&D center covering 20,000 square meters. It also has a more than 4,000 square meters aseptic purification cleanroom meeting GMP standards.
Lansionbio has always been upholding innovation, committing to breakthroughs, insisting on the R&D work from the beginning. It has already built up 3 world-leading platforms: microfluidics, immunochromatography and molecular diagnosis. The company's products have been exported to nearly 100 countries and regions and can meet the medical needs of over 30,000 health facilities and 200 million families.
The company's competitors include Bioeast (Chinese: 博岳生物), ThunderBio (Chinese: 达普生物) and Thinkaribio (Chinese: 芯凯瑞).